Niagen Bioscience CEO to Outline Pharmaceutical Strategy in July Fireside Chat — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience CEO Rob Fried will participate in a virtual fireside chat on July 15, 2026, at 8 am PDT.
The discussion will focus on the company's pharmaceutical program for rare genetic diseases and aging-related disorders.
Fried will provide updates on Niagen Bioscience's business and its leadership in NAD+ science.
The event includes a live Q&A session moderated by Valter Pinto of KCSA Strategic Communications.

The big picture

Niagen Bioscience is pivoting from consumer supplements to pharmaceutical development, a strategic shift that could broaden its market reach and revenue streams. The company's focus on rare genetic diseases and aging-related disorders aligns with broader industry trends toward precision medicine and healthspan extension. Success in this transition will depend on regulatory approvals and clinical trial outcomes.

What we're watching

Pharmaceutical Expansion: How the company's shift into pharmaceutical development for rare genetic diseases will impact its growth trajectory.
Regulatory Milestones: The pace at which Niagen Bioscience can advance its NB4168 molecule through preclinical and clinical trials.
Market Positioning: Whether Niagen Bioscience can maintain its leadership in NAD+ science while expanding into the pharmaceutical sector.